The Global Human Papillomavirus (HPV) and Cytomegalovirus(CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 3,006.4 million in 2018, and is projected to exhibit a CAGR of 6.0%, during the forecast period (2018 - 2026), as highlighted in a new report published by Coherent Market Insights.

Browse 37 Market Data Tables and 33 Figures spread through 167 Pages and in-depth TOC on " Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

Cytomegalovirus (CMV) is also known as Human Herpes Virus 5 (HHV-5). This virus is most commonly transmitted to a developing fetus. It affects males and females equally at any age. For instance, in January 2018, according to Centers for Disease Control and Prevention (CDC), around 50% adults suffer from CMV infections in U.S. Increasing approval activities for novel therapies is expected to drive the market growth.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/human-papillomavirus-hpv-and-cytomegalovirus-cmv-therapeutics-market-2707

For instance, in January 2016, Fate Therapeutics Inc. received approval from the U.S. Food and Drug Administration for its new programmed cellular immunotherapy ProTmune. It is used for prevention of acute CMV infection and GvHD (Graft- versus-Host Disease) infection.

Consistent research and development activities for the treatment of HPV and CMV infections is expected to boost the human papillomavirus and cytomegalovirus therapeutics market growth during the forecast period. For instance, in May 2014, Atara Biotherapeutics initiated clinical study of preemptive adoptive CMV-specific T cells (CMVpp65) infusion for prevention of refractory CMV infection in patients. These cells can restore antiviral immunity and clear CMV infection after allogeneic hematopoietic stem cell transplantation. This study is expected to complete in June 2019.

Furthermore, in July 2012, University of Alabama at Birmingham initiated clinical phase II study of quadrivalent HPV recombinant vaccine. It is used for the treatment of HPV (types 6, 11, 16, 18) infections. This study is expected to complete in November 2020. In January 2018, Shire Company received approval from the U.S. Food and Drug Administration for its new investigational treatment drug Maribavir (SHP620). This drug is used for the treatment of CMV infections.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2707

Key Takeaways of the Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market:

The global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market is expected to witness a CAGR of 6.0% during the forecast period (2018 – 2026), owing to increasing prevalence of cervical cancer in U.S. For instance, according to WHO (World Health Organization) report 2018, around 570,000 women suffer from cervical cancer and in 2018 around 311000 women died from cervical cancer worldwide.

Among regions, North America is expected to hold largest market share for human papillomavirus (HPV) and cytomegalovirus (CMV) market, owing to increasing approval activities by the U.S. Food and Drug Administration. For instance, in June 2018, the U.S. Food and Drug Administration announced approval of Keytruda (Contains-Pembrolizumab), which is used for the treatment of PD-L1–positive cervical cancer.
Major players operating in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market include, Allergan, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2707

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737